A U.S.-funded study on hepatitis B vaccines targeting infants in Guinea-Bissau has garnered significant controversy and scrutiny amid ethical concerns. The trial, backed by the Trump administration, was initially touted for its potential benefits but has been halted pending an ethical review by health officials. Critics have drawn comparisons to the infamous Tuskegee Experiment, with accusations that the study could place African newborns at risk. Despite backlash and calls for cancellation, U.S. officials maintain that the study will proceed, leading to confusion and debate over its ethical implications. The World Health Organization and UNICEF are also monitoring the situation closely, as health officials in Guinea-Bissau emphasize the need for careful consideration before restarting the trial.